One reason given for proactive participation and earlier submission of a monograph was the possibility of prospective or informal harmonization across multiple pharmacopoeias. It is instructive to ...
The European Pharmacopoeia Commission re-evaluates its policy on the development of monographs for finished drug products. The European Pharmacopoeia (Ph.Eur.), which is celebrating its 50th ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results